A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
Inclusion Criteria
- Written informed consent, Release of Medical Records Form and HIPAA reviewed and signed by patient or legally authorized representatives
- Ability to understand and the willingness to sign a written informed consent document.
- creatinine < 2 mg/dL
- ...
- Written informed consent, Release of Medical Records Form and HIPAA reviewed and signed by patient or legally authorized representatives
- Ability to understand and the willingness to sign a written informed consent document.
- creatinine < 2 mg/dL
- Any Grade 3 or 4 toxicities (according to NCI CTCAE) resolved for at least 2 weeks prior to first treatment
- hemoglobin (Hgb) > 9.9 g/dL
- alkaline phosphatase (ALP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 4x upper limit of normal (ULN)
- blood urea nitrogen (BUN) < 30 mg/dL
- Any recurrence of a glioblastoma multiforme
- absolute neutrophil count (ANC) > 1000/mm3
- platelet count > 100,000/mm3
- If not surgically sterile, male and female patients of childbearing age must use double barrier contraception (hormonal; intrauterine device; barrier)
- Karnofsky Performance Score (KPS) of ≥ 70%
- ≥ 18 years of age
- Human leukocyte antigen HLA A2 positive
- Female patients of child bearing potential must have negative serum pregnancy test
- prothrombin time (PT) and activated partial thromboplastin time (PTT) ≤ 1.6 x control unless therapeutically warranted
Exclusion Criteria
- Radiosurgery including Gamma Knife, linear accelerator based radiosurgery, CyberKnife and placement of Gliadel wafer
- Known history of an autoimmune disorder
- Contraindication to MRI
- ...
- Radiosurgery including Gamma Knife, linear accelerator based radiosurgery, CyberKnife and placement of Gliadel wafer
- Known history of an autoimmune disorder
- Contraindication to MRI
- Foreseeable condition which would preclude the reduction of steroids (dexamethasone) to a maximum of 2 mg BID within a week prior to apheresis -
- Presence of any other active malignancy or prior history of malignancy, except for: basal cell carcinoma of the skin, cervical carcinoma in situ, early stage prostate carcinoma not requiring active treatment
- Known human immunodeficiency virus positivity or acquired immunodeficiency syndrome related illness or other serious medical condition
- Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes);
- New York Heart Association >/= Grade 3 congestive heart failure within 6 months prior to study entry
- Clinically significant abnormality on electrocardiogram (ECG)
- Immunosuppressive disease
- Diagnosed or suspected congenital long QT syndrome
- Received any other therapeutic investigational agent within 30 days of screening, except for immunotherapy. Patients with previous immunotherapy are not eligible regardless of timing.
- Uncontrolled angina within 6 months
- Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of the protocol.
- Breastfeeding
- Presence of an acute infection requiring active treatment with antibiotics/antivirals; prophylactic administration is allowed
- Chronic renal disease / failure
- Myocardial infarction and transient ischemic attack or stroke within 6 months prior to enrollment
- Pulmonary disease including or greater than grade 2 dyspnea or laryngeal edema, grade 3 pulmonary edema or pulmonary hypertension according to CTCAE 4.03
- Concurrent neurodegenerative disease,
Summary
- Conditions
- Glioblastoma Multiforme
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Immunotherapy holds promise in oncology for the potential to provide targeted anti-tumor therapy with minimal adverse events. The goal of this study is to assess immunotherapy directed to CD133 in an autologous dendritic cell product called ICT-121. CD133 antigen is overexpressed on many types of ca...
Immunotherapy holds promise in oncology for the potential to provide targeted anti-tumor therapy with minimal adverse events. The goal of this study is to assess immunotherapy directed to CD133 in an autologous dendritic cell product called ICT-121. CD133 antigen is overexpressed on many types of cancer cells and is associated with shortened survival. CD133 positive cancer stem cells are resistant to chemotherapy. Patients with recurrent glioblastoma who have the HLA A2 phenotype will receive autologous vaccine of DC pulsed with purified peptides from CD133. Approximately 20 patients with any recurrence of glioblastoma multiforme (GBM) will be treated. After informed consent and screening, patients will undergo apheresis to collect peripheral blood mononuclear cells (PBMCs). Monocytes will be purified and cultured into dendritic cells (DC) that are pulsed with purified peptides from CD133 antigen. The pulsed dendritic cells will then be aliquoted and frozen. Patients will have the autologous DCs reinfused intradermally. Patients will receive at least four intradermal injections of the autologous DC vaccine and additional vaccines during a maintenance phase. The goal is to induce a cytotoxic T cell response to CD133 positive cells. The primary objective of the study is to assess safety and tolerability. Clinical response rates will be monitored as well as the immune responses to CD133.
Inclusion Criteria
- Written informed consent, Release of Medical Records Form and HIPAA reviewed and signed by patient or legally authorized representatives
- Ability to understand and the willingness to sign a written informed consent document.
- creatinine < 2 mg/dL
- ...
- Written informed consent, Release of Medical Records Form and HIPAA reviewed and signed by patient or legally authorized representatives
- Ability to understand and the willingness to sign a written informed consent document.
- creatinine < 2 mg/dL
- Any Grade 3 or 4 toxicities (according to NCI CTCAE) resolved for at least 2 weeks prior to first treatment
- hemoglobin (Hgb) > 9.9 g/dL
- alkaline phosphatase (ALP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 4x upper limit of normal (ULN)
- blood urea nitrogen (BUN) < 30 mg/dL
- Any recurrence of a glioblastoma multiforme
- absolute neutrophil count (ANC) > 1000/mm3
- platelet count > 100,000/mm3
- If not surgically sterile, male and female patients of childbearing age must use double barrier contraception (hormonal; intrauterine device; barrier)
- Karnofsky Performance Score (KPS) of ≥ 70%
- ≥ 18 years of age
- Human leukocyte antigen HLA A2 positive
- Female patients of child bearing potential must have negative serum pregnancy test
- prothrombin time (PT) and activated partial thromboplastin time (PTT) ≤ 1.6 x control unless therapeutically warranted
Exclusion Criteria
- Radiosurgery including Gamma Knife, linear accelerator based radiosurgery, CyberKnife and placement of Gliadel wafer
- Known history of an autoimmune disorder
- Contraindication to MRI
- ...
- Radiosurgery including Gamma Knife, linear accelerator based radiosurgery, CyberKnife and placement of Gliadel wafer
- Known history of an autoimmune disorder
- Contraindication to MRI
- Foreseeable condition which would preclude the reduction of steroids (dexamethasone) to a maximum of 2 mg BID within a week prior to apheresis -
- Presence of any other active malignancy or prior history of malignancy, except for: basal cell carcinoma of the skin, cervical carcinoma in situ, early stage prostate carcinoma not requiring active treatment
- Known human immunodeficiency virus positivity or acquired immunodeficiency syndrome related illness or other serious medical condition
- Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes);
- New York Heart Association >/= Grade 3 congestive heart failure within 6 months prior to study entry
- Clinically significant abnormality on electrocardiogram (ECG)
- Immunosuppressive disease
- Diagnosed or suspected congenital long QT syndrome
- Received any other therapeutic investigational agent within 30 days of screening, except for immunotherapy. Patients with previous immunotherapy are not eligible regardless of timing.
- Uncontrolled angina within 6 months
- Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of the protocol.
- Breastfeeding
- Presence of an acute infection requiring active treatment with antibiotics/antivirals; prophylactic administration is allowed
- Chronic renal disease / failure
- Myocardial infarction and transient ischemic attack or stroke within 6 months prior to enrollment
- Pulmonary disease including or greater than grade 2 dyspnea or laryngeal edema, grade 3 pulmonary edema or pulmonary hypertension according to CTCAE 4.03
- Concurrent neurodegenerative disease,
Tracking Information
- NCT #
- NCT02049489
- Collaborators
- Not Provided
- Investigators
- Study Director: Anthony Gringeri, Ph.D. Precision Life Sciences Group
Get Well Soon